Back
ESC Professional Premium Access

Sacubitril/valsartan versus enalapril in chronic chagas cardiomyopathy: baseline characteristics of the PARACHUTE-HF trial

Session: Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure
Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)
Speaker: Professor R. Lopes (Durham, US)
Event: ESC Congress 2024

Congress Presentation

Add to my library

Like

About the speaker

Professor Renato Lopes

Duke University Medical Center, Durham (United States of America)
31 presentations
2 followers

7 more presentations in this session

Guideline-directed medical therapy patterns in heart failure with reduced ejection fraction: the OPTIMA-HF registry

Speaker: Doctor S. Paolillo (Naples, IT)

Access
Abstract
Slides
Like
Thumbnail

Quality of life in patients with heart failure and improved ejection fraction: one-year follow-up with ARNI and SGLT2i

Speaker: Professor S. Tadic (Novi Sad, RS)

Access
Abstract
Slides
Like
Thumbnail

Real world evidence of Sacubitril/Valsartan in octogenarian patients with heart failure. Results From the PARACHUTE-HF Study

Speaker: Doctor N. Okuda (Kawagoe, JP)

Access
Abstract
Slides
Like
Thumbnail

Estimated plasma volume in heart failure with reduced ejection fraction: ACE inhibitors versus angiotensin receptor/neprilysin inhibitor in follow up

Speaker: Doctor S. Varga (Sisak, HR)

Access
Abstract
Slides
Like
Thumbnail

Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i

Speaker: Mrs O. Obertynska (Vinnitsa, UA)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure

Speakers: Professor R. Lopes, Doctor S. Paolillo, Professor S. Tadic, Doctor N. Okuda, Doctor S. Varga...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources